Georgetown Doc Works Toward Personalized Cancer Care | WAMU 88.5 - American University Radio

WAMU 88.5 : Metro Connection

Filed Under:

Georgetown Doc Works Toward Personalized Cancer Care

Play associated audio
Dr. Richard Schlegel, Chair of Georgetown University Medical Center's Department of Pathology
Jonathan Wilson
Dr. Richard Schlegel, Chair of Georgetown University Medical Center's Department of Pathology

About seven years ago, the laboratory run by Dr. Richard Schlegel at Georgetown University's Department of Pathology developed the technology for the first vaccine for Human Papillomavirus or HPV — a virus that can lead to cervical cancer. Now Dr. Schlegel's lab appears to have made another big discovery — one that could eventually change the way doctors treat all kinds of cancer. Metro Connection's Jonathan Wilson talked with doctor in his office at Georgetown University to find out what the lab's latest breakthrough medical trial revealed.

Dr. Schlegel explaining the concept of reprogrammed cells: "The finding that we have come upon, is that we have a way to grow normal and tumor cells from a patient very rapidly and very efficiently, which hasn't been able to be accomplished before. What it allows us to be able to do now is to go in and take a biopsy of someone's tumor, with a needle, for example, like a breast tumor if you had a biopsy, and within days have tumor cells growing out of there and normal cells if you have a normal area. So you can identify drugs that kill the tumor cells, and not the normal cells."

On how it could change cancer treatments: "You may have a drug that's known, to say, treat a lung tumor, in most cases, you'll get a response, but they [the tumors] come back. And then it becomes a game of oncology experimentation. I hate to say that, but you know, you don't know what's going to work, but you try another drug on the patient. And if it works, good, if it doesn't you move on to another one. The bad thing about that is every time you use a new drug on a patient, there's a lot of toxicity associated with it. So with each different round of chemotherapy, the patient gets sicker and sicker. So what we're able to do with this, we hope — when it gets tested in much larger trials — is to use the laboratory to define the spectrum of drugs that would be good to use on the patient and avoid all of the toxicities. We are not just going to take a drug off the shelf - drug 'x' is best for this population of patients who have lung tumors. We will actually take your tumor, and find out what drug is best for you. That's the ultimate goal."

Dr. Schlegel and his researchers caution that it could be years before validation studies on their work is completed, and government approval is granted for broader use of the new technique.


[Music: "House MD Theme" by Massive Attack from House MD Original Television Soundtrack]

NPR

Buzz Bissinger: With Caitlyn Jenner, 'You Feel A Connection'

NPR's Melissa Block interviews Buzz Bissinger about his profile of Caitlyn Jenner in Vanity Fair and her gender transition. She is formerly known as Bruce, an Olympic gold medalist in the decathlon.
NPR

Grass Gourmands: A Herbivore Food Mystery On The African Savanna

A new study sheds light on a longstanding ecological question: How do so many species like impalas and elephants co-exist when they're all feeding on the same limited foods?
NPR

House Panel Questions Air Bag Manufacturer About Chemical Explosive It Uses

Lawmakers wanted to know more about the recall of some 34 million vehicles that have potentially defective air bags made by the Takata Corporation. Congress wants to know what caused the problem.
NPR

A Taxi App Aims To Build Trust Where Crime Is High

In Nairobi, people don't like getting into cabs driven by strangers. They prefer to call drivers they know or who their friends recommend. A new app assigns drivers a trust score based on social ties.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.